Viatris  logo
Viatris VTRS
$ 17.56 -1.13%
report update icon

Quarterly report 2026-Q1
added 05-07-2026

Viatris Income Statement 2025-2011 | VTRS

Brief overview of revenue and earnings at Viatris

The conclusions below are based on five years of reported results. Revenue reported by Viatris was 11.9 billion dollars at the beginning of the period and 14.3 billion dollars at the end. The total change was +19.7%, with a CAGR of approximately 3.7%. Sales changed only slightly and remained broadly flat.

Gross profit was 3.8 billion dollars at the start and 5 billion dollars at the end of the period (+32%). The relationship between sales and direct costs improved over the period. At the margin level, the figure shifted from 31.8% to 35.1%. Improving gross profitability strengthens the quality of revenue growth.

The five-year EBITDA result moved by −93.3%: from 2 billion dollars to 135 million dollars. EBITDA underperformed the top-line trend. The EBITDA share of revenue changed from 16.8% to 0.9%. The business retained less EBITDA from each unit of revenue.

Across the five years, the net result shifted from −$670 million to −$3.5 billion. Profitability deteriorated further over the five years.

Conclusion

The results contain several connected negative signals. The constructive conclusion rests on better sales economics. The most visible risks are a declining EBITDA margin, lower net income and a narrow EBITDA buffer. The key question is whether sales can be converted into sustainable profit.

Annual Income Statement Viatris

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- - 18.4 B 13.6 B 13.3 B 8.86 B 11.3 B 15.9 B 23.5 B 18.6 B 24.9 B 19.9 B 17.5 B 11.7 B 9.04 B

Shares

- - 1.2 B 1.21 B 1.21 B 601 M 516 M 514 M 534 M 513 M 472 M 374 M 383 M 415 M 431 M

Historical Prices

8.69 10.6 15.3 11.2 11 14.7 17.1 26.2 40 41.6 44.8 56.9 55.2 29.4 23.3

Net Income

-3.51 B -634 M 54.7 M 2.08 B -1.27 B -670 M 16.8 M 352 M 696 M 480 M 848 M 929 M 624 M 641 M 537 M

Revenue

14.3 B 14.7 B 15.4 B 16.3 B 17.9 B 11.9 B 11.5 B 11.4 B 11.9 B 11.1 B 9.43 B 7.72 B 6.91 B 6.8 B 6.13 B

Cost of Revenue

9.29 B 9.12 B 8.99 B 9.77 B 12.3 B 8.15 B 7.6 B 7.43 B - - - - - - -

Gross Profit

5.01 B 5.62 B 6.44 B 6.5 B 5.58 B 3.8 B 3.9 B 4 B 4.78 B 4.7 B 4.22 B 3.53 B 3.04 B 2.91 B 2.56 B

Operating Income

-2.66 B 10.1 M 766 M 1.61 B -34 M -211 M 716 M 906 M - - - - - - -

Interest Expense

471 M 550 M 573 M 592 M 636 M 498 M 517 M 542 M - - - - - - -

EBITDA

135 M 2.9 B 3.51 B 4.64 B 4.47 B 2.01 B 2.71 B 2.97 B 3.23 B 2.9 B 2.4 B 1.97 B 1.64 B 1.65 B 1.56 B

Operating Expenses

7.68 B 5.61 B 5.67 B 4.88 B 5.61 B 4.01 B 3.2 B 3.15 B 3.36 B 3.32 B 2.85 B 2.13 B 1.92 B 1.8 B 1.51 B

General and Administrative Expenses

3.79 B 4.1 B 4.07 B 4.18 B 4.53 B 3.34 B - - - - - - - - -

All numbers in USD currency

Quarterly Income Statement Viatris

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

1.16 B 1.16 B 1.17 B 1.19 B 1.19 B 1.19 B 1.2 B 1.2 B 1.2 B 1.2 B - 1.21 B 1.21 B 1.21 B - 1.21 B 1.21 B 1.21 B - 517 M 517 M 516 M 100 100 100 100 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

176 M -128 M -4.6 M -3.04 B 94.8 M -326 M 114 M 332 M 264 M 225 M - 354 M 314 M 399 M - 312 M -279 M -1.04 B - -169 M -900 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

3.52 B 3.76 B 3.58 B 3.25 B 3.75 B 3.8 B 3.66 B 3.94 B 3.92 B 3.73 B - 4.08 B 4.12 B 4.19 B - 4.54 B 4.58 B 4.43 B - 2.97 B 2.73 B 2.62 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

2.36 B 2.39 B 2.25 B 2.09 B 2.29 B 2.35 B 2.16 B 2.25 B 2.31 B 2.19 B - 2.33 B 2.41 B 2.42 B - 2.96 B 3.25 B 3.3 B - 1.81 B 1.71 B 1.71 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

1.16 B 1.37 B 1.33 B 1.16 B 1.46 B 1.45 B 1.5 B 1.69 B 1.61 B 1.54 B - 1.75 B 1.7 B 1.77 B - 1.57 B 1.33 B 1.13 B - 1.16 B 1.03 B 906 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-79.7 M 179 M 233 M -2.88 B 226 M -240 M 204 M 452 M 369 M 400 M - 560 M 549 M 707 M - 358 M -47.8 M -266 M - 351 M 134 M 185 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

120 M 120 M 117 M 116 M 146 M 146 M 138 M 142 M 144 M 147 M - 153 M 146 M 146 M - 152 M 167 M 169 M - 117 M 116 M 120 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

596 M 772 M 816 M -2.22 B 801 M 357 M 895 M 1.04 B 960 M 1.13 B - 2.72 B 1.18 B 1.44 B - 4.11 B 2.69 B 1.16 B - 1.61 B 965 M 600 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

1.24 B 1.19 B 1.1 B 4.04 B 1.23 B 1.69 B 1.3 B 1.24 B 1.24 B 1.14 B - 1.19 B 1.15 B 1.06 B - 1.22 B 1.38 B 1.39 B - 807 M 892 M 721 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

929 M 887 M 929 M 948 M 1 B 1.04 B 1.02 B 1.05 B 1.03 B 959 M - 1.02 B 981 M 915 M - 1.06 B 1.2 B 1.19 B - 658 M 719 M 605 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Viatris (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Drug manufacturers industry

Issuer Price % 24h Market Cap Country
ProPhase Labs ProPhase Labs
PRPH
- - $ 5.07 M usaUSA
Endo International plc Endo International plc
ENDP
- - $ 28.9 M irlandaIrlanda
Evoke Pharma Evoke Pharma
EVOK
- - $ 36.6 M usaUSA
HEXO Corp. HEXO Corp.
HEXO
- 2.45 % $ 38.1 M canadaCanada
Calliditas Therapeutics AB (publ) Calliditas Therapeutics AB (publ)
CALT
- -0.1 % $ 2.03 B schwedenSchweden
AcelRx Pharmaceuticals AcelRx Pharmaceuticals
ACRX
- 7.5 % $ 6.35 M usaUSA
DURECT Corporation DURECT Corporation
DRRX
- - $ 50.1 M usaUSA
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation
ADMP
- 0.86 % $ 117 M usaUSA
Aerie Pharmaceuticals Aerie Pharmaceuticals
AERI
- - $ 754 M usaUSA
Agile Therapeutics Agile Therapeutics
AGRX
- 10.11 % $ 58.2 M usaUSA
Alimera Sciences Alimera Sciences
ALIM
- - $ 142 M usaUSA
Perrigo Company plc Perrigo Company plc
PRGO
$ 10.11 -1.89 % $ 1.4 B usaUSA
Rockwell Medical Rockwell Medical
RMTI
$ 7.19 1.27 % $ 259 M usaUSA
Athenex Athenex
ATNX
- -23.39 % $ 1.76 M usaUSA
Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc
AVDL
- - $ 2.06 B franceFrance
Sonoma Pharmaceuticals Sonoma Pharmaceuticals
SNOA
$ 1.1 -2.65 % $ 1.85 M usaUSA
Catalent Catalent
CTLT
- - $ 11.5 B usaUSA
Eagle Pharmaceuticals Eagle Pharmaceuticals
EGRX
- -39.89 % $ 27.7 M usaUSA
Cronos Group Cronos Group
CRON
$ 2.83 -2.08 % $ 1.09 B canadaCanada
Veru Veru
VERU
$ 2.24 0.9 % $ 32.8 M usaUSA
Jupiter Wellness Jupiter Wellness
JUPW
- - $ 33.6 M usaUSA
Lannett Company Lannett Company
LCI
- 1.15 % $ 7.11 M usaUSA
cbdMD cbdMD
YCBD
$ 0.51 4.36 % $ 2.05 M usaUSA
Canopy Growth Corporation Canopy Growth Corporation
CGC
$ 0.92 -0.08 % $ 274 M canadaCanada
Cumberland Pharmaceuticals Cumberland Pharmaceuticals
CPIX
$ 6.68 -0.74 % $ 99.2 M usaUSA
Neoleukin Therapeutics Neoleukin Therapeutics
NLTX
- - $ 193 M canadaCanada
Assertio Holdings Assertio Holdings
ASRT
- - $ 150 M usaUSA
Radius Health Radius Health
RDUS
- - $ 1.42 B usaUSA
PetIQ PetIQ
PETQ
- 1.64 % $ 400 M usaUSA
Recro Pharma Recro Pharma
REPH
- -4.76 % $ 65.3 M usaUSA
OptiNose OptiNose
OPTN
- - $ 1.08 B usaUSA
PLx Pharma PLx Pharma
PLXP
- -27.8 % $ 2.56 M usaUSA
Zynerba Pharmaceuticals Zynerba Pharmaceuticals
ZYNE
- - $ 55.5 M usaUSA
Zomedica Corp. Zomedica Corp.
ZOM
- -0.21 % $ 98 M usaUSA
Tricida Tricida
TCDA
- - $ 3.25 M usaUSA
Bausch Health Companies Bausch Health Companies
BHC
$ 6.89 14.36 % $ 2.56 B canadaCanada
Emergent BioSolutions Emergent BioSolutions
EBS
$ 7.22 -0.55 % $ 386 M usaUSA
OrganiGram Holdings OrganiGram Holdings
OGI
$ 0.94 -2.96 % $ 89.6 M canadaCanada
China Pharma Holdings China Pharma Holdings
CPHI
$ 1.11 -12.6 % $ 4.76 M chinaChina
Aurora Cannabis Aurora Cannabis
ACB
$ 2.79 -1.41 % $ 153 M canadaCanada
Harrow Health Harrow Health
HROW
$ 38.77 -0.44 % $ 1.43 B usaUSA
Evolus Evolus
EOLS
$ 5.84 -2.83 % $ 376 M usaUSA
SCYNEXIS SCYNEXIS
SCYX
$ 4.84 30.46 % $ 242 M usaUSA
Solid Biosciences Solid Biosciences
SLDB
$ 8.06 -5.06 % $ 705 M usaUSA
Relmada Therapeutics Relmada Therapeutics
RLMD
$ 5.31 -0.75 % $ 210 M usaUSA
Organogenesis Holdings Organogenesis Holdings
ORGO
$ 2.37 -3.27 % $ 300 M usaUSA
Pacira BioSciences Pacira BioSciences
PCRX
$ 26.41 -2.08 % $ 1.22 B usaUSA
TherapeuticsMD TherapeuticsMD
TXMD
$ 2.03 - $ 23.5 M usaUSA
Sundial Growers Sundial Growers
SNDL
$ 1.23 -1.6 % $ 317 M canadaCanada
Tilray Tilray
TLRY
$ 4.54 8.1 % $ 4.04 B canadaCanada